Small biotech Oys­ter Point sets up pitch to dis­rupt dry eye mar­ket with nasal spray

Oys­ter Point Phar­ma — a small Prince­ton, NJ-based biotech look­ing to dis­rupt a mas­sive eye drug mar­ket large­ly mo­nop­o­lized by two ther­a­pies — has pos­i­tive piv­otal tri­al da­ta as it march­es on a path to­wards US ap­proval.

Oys­ter, which went pub­lic in an $80 mil­lion IPO last year, has a nasal for­mu­la­tion of vareni­cline —a for­mu­la­tion of Pfiz­er’s smok­ing-ces­sa­tion drug Chan­tix — it is de­vel­op­ing for dry eye dis­ease, a chron­ic, episod­ic dis­ease af­fect­ing the tears and oc­u­lar sur­face that af­fects some 33 mil­lion Amer­i­cans.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER